Table 2 Comparison between UHBFT patients that experienced a VTE episode during follow-up versus those that did not

Median age at diagnosis in years (IQR)

57 (45–68)

61 (52–69)

0.235

Male gender

120 (52%)

19 (63%)

0.259

GPA

142 (62%)

18 (60%)

0.670

MPA

82 (36%)

12 (40%)

CSS

5 (2%)

0

PR3 +ve

131 (57%)

20 (67%)

0.323

MPO +ve

98 (43%)

10 (33%)

Caucasian ethnicity

207 (90%)

27 (90%)

0.945

CMV seropositive

132 (58%)

25 (83%)

0.007

Induction treatment:

 Cyclophosphamide

176 (78%)

23 (85%)

0.343

 Rituximab

8 (4%)

0

0.322

 Cyclophosphamide and rituximab

4 (2%)

0

0.487

 Azathioprine

17 (7%)

1 (4%)

0.469

 Mycophenolate mofetil

12 (5%)

3 (11%)

0.225

 Methotrexate

7 (3%)

0

0.355

Organ involvement

 Renal

154 (67%)

25 (83%)

0.073

 ENT

58 (25%)

4 (13%)

0.148

 Pulmonary haemorrhage

23 (10%)

1 (3%)

0.233

 Lung

64 (28%)

4 (13%)

0.087

 Nervous system

20 (9%)

2 (7%)

0.703

 Eye

21 (9%)

1 (3%)

0.281

Dialysis requirement at diagnosis or during follow-up

35 (13%)

10 (33%)

0.014

Median creatinine at diagnosis μmol/L (IQR)

164 (91–389)

241 (163–593)

0.062

Median CRP at diagnosis mg/L (IQR)

44 (14–132)

139 (63–244)

< 0.001

Median urine ACR at diagnosis mg/mmol (IQR)

31 (2–120)

90 (16–314)

0.112

Median serum albumin at diagnosis g/L (IQR)

35 (30–40)

33 (29–37)

0.107

Median Hb at diagnosis g/L (IQR)

100 (88–122)

96 (88–118)

0.313

VTE event pre-AAV diagnosis

5 (2%)

2 (7%)

0.154

Malignancy at diagnosis of AAV

3 (1%)

1 (3%)

0.398

Malignancy at diagnosis of VTE or end of f/u

24 (11%)

2 (7%)

0.513

Warfarin at diagnosis of AAV

3 (1%)

1 (3%)

0.392